Clinical trials: Dermatitis Eczema
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
The aim of this study is to evaluate the tolerance and efficacy of a new emollient cream specifically dedicated to the eyelid area when applied in association with tacrolimus 0.1% in subjects suffering from eyelid Atopic…
- Trial name
- NCT07819071
- Testing
- Tested Emollient RV5258A, tacrolimus 0.1%
- Where
- Poland
- Volunteers
- 33 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- CAN UpTIMISE (NCT05394792)
- Where
- 25 sites in Canada
- Volunteers
- 111 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis
The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis.
- Trial name
- NCT02583022
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream vehicle, Elidel cream 1%
- Volunteers
- 74 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT04140695
- Testing
- Tradipitant
- Where
- 51 sites in United States
- Volunteers
- 87 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis (AD)
A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
Atopic Dermatitis (AD) is a common, chronic, and flaring systemic inflammatory skin disorder characterized by intensely pruritic and distressing skin eruptions.
- Trial name
- NCT06503536
- Where
- China
- Volunteers
- 150 people
- Sponsor
- AbbVie
Dermatitis, Atopic
An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of tacrolimus ointment in treating the signs and symptoms of moderate (medium level of seriousness) to severe (very serious, life threatening) atopic dermatitis (an…
- Trial name
- NCT01782729
- Testing
- Tacrolimus
- Where
- Vietnam
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Atopic Dermatitis, Eczema
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds.
- Trial name
- NCT00076375
- Testing
- Nanocrystalline silver cream (NPI)
- Where
- 19 sites in United States
- Volunteers
- 180 people
- Sponsor
- Nucryst Pharmaceuticals
Atopic Dermatitis
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: 14 weeks of treatment with tralokinumab a single dose of tralokinumab
- Trial name
- NCT03556592
- Testing
- Tralokinumab, Caffeine, Warfarin
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.
- Trial name
- AD (NCT04539639)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Atopic Dermatitis
CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS
his was a monocentric, intra-individual study, that was performed in at least 45 valid cases (50% children ≥3 YO; 50% adults). Study duration was 168 days with five (5) visits (D0, D14, D28, D84 and D168) to the research center.
- Trial name
- NCT05783453
- Testing
- Cosmetic study
- Where
- Brazil
- Volunteers
- 63 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis
Atopic dermatitis represents a real challenge in public health as it affects a large percentage of children and adults. Affected individuals must cope with a significant psychosocial burden, in addition to dealing with the…
- Trial name
- NCT04553224
- Testing
- Clinical evaluations, Non-invasive instrumental measurements, Subject's evaluations
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Safety Issues
A Phase I Clinical Study of Hemay808
This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028.
- Trial name
- NCT04100642
- Testing
- Hemay808
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in…
- Trial name
- NCT03908970
- Testing
- 1% OPA-15406
- Where
- Japan
- Volunteers
- 364 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy Adults
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves.
- Trial name
- NCT07284173
- Testing
- PF-08049820, Rabeprazole
- Where
- 2 sites in China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety profiles of E6005 ointment in patients with atopic dermatitis compared to vehicle. The pharmacokinetic profile after topical application of E6005 is also assessed.
- Trial name
- NCT01461941
- Testing
- E6005, E6005 ointment (vehicle)
- Where
- 10 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05048056
- Testing
- AK120
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Akesobio Australia Pty Ltd
Chronic Pruritus, Atopic Dermatitis
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).
- Trial name
- BLUEPRINT (NCT04693195)
- Testing
- BLU-5937
- Where
- 33 sites in United States, Canada
- Volunteers
- 142 people
- Sponsor
- Bellus Health Inc. - a GSK company
Atopic Dermatitis
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the…
- Trial name
- NCT03725722
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 251 people
- Sponsor
- LEO Pharma
Healthy, Atopic Dermatitis
A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis
This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese…
- Trial name
- NCT03260595
- Testing
- Crisaborole ointment 2%, Vehicle
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
- Trial name
- Adoring (NCT07265479)
- Testing
- Tapinarof cream, 1%, Vehicle Cream
- Where
- 46 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.